Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525546 · ClinicalTrials.gov registry record · Phase 1
Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT05525546 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 82 participants.
The verdict
NCT05525546, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
Interventions
- OTHER Placebo
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
- BIOLOGICAL Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05525546
The ClinicalTrials.gov registry entry for NCT05525546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05525546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05525546 about?
NCT05525546 is a clinical study titled "Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease". This is a randomized, placebo-controlled interventional study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
What is the current status of trial NCT05525546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2022-08-15. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT05525546?
The interventions under investigation include: Placebo (OTHER), Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation (BIOLOGICAL), Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation (BIOLOGICAL), Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05525546?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.